Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent ...

Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies, ...

Quantum Biopharma has filed with the FDA to start a Phase 2 trial of Lucid-MS to assess the treatment's ability to halt ...

Telmisartan, an FDA-approved blood pressure drug, could boost a certain cancer treatment's effectiveness against tumors, a ...

An executive order upended an NIH policy requiring researchers to account for both sexes in preclinical animal studies.

Sponsors will now be able to submit preclinical toxicology data using virtual animal controls instead of a standard animal control group in relevant contexts.

A new preclinical study found that inhibiting the enzyme LSD1 can activate the skin’s immune system and suppress tumor growth ...

High-dose vitamin B3 (niacin) may boost immune function and slow glioblastoma progression, with 82% of trial patients showing ...

Performance driven by core drug discovery, continued adoption in environmental toxicology, and launch of new assays and ...

Nuclide Therapeutics Leverages Enamine's Deep Expertise in Rapid and Scalable Synthesis of Small Molecules KYIV, ...

A compound isolated from an edible mushroom may hold the potential as an anti-cancer agent against melanoma, according to a ...

First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a ...